POTELIGEO (Mogamulizumab)
mogamulizumab 20 mg/5 mL injection, 5 mL vial · INJECTION · PBS code 15306N
AUTHORITY_REQUIREDWhat it costs
AU$2183 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-04-01.
- • Repeats: 3.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Cutaneous T-cell lymphoma
Initial treatment
Patient must have received systemic treatment with chemotherapy; AND
Patient must demonstrate relapsed or chemotherapy-refractory disease; AND
Patient must be ineligible for stem cell transplant; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
If the application is submitted through HPOS form upload or mail, it must include:
(i) details of the proposed prescription; and
(ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).
Sponsor: KYOWA KIRIN AUSTRALIA PTY LTD ABN 47 631 934 453
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.